Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Cline, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.
Article
24 July 2024 - by Gabriela Dieguez, Tyler Engel, James Burke
We examined utilization and reimbursement patterns of COVID-19 tests in the commercially-insured population.
Article
23 May 2024 - by Hanaa Siddiqi, Siyi Lu, Carol Bazell, Gabriela Dieguez, Dagny Grillis
As part of an analysis for Sanofi U.S., we examine the economic implications of kidney transplants, including hospital expense and Medicare allowed costs.
Article
21 December 2023 - by Jennifer Carioto, Gabriela Dieguez, Tushar Makhija
We expect the financial implications of the Inflation Reduction Act to lead to a reassessment of formulary strategies by Medicare Part D plans.
Article
15 February 2022 - by Gabriela Dieguez, Jennifer Carioto
Quantifying the impact of expanding biomarker testing coverage in the commercial and Medicaid markets.
Article
13 July 2021 - by Gabriela Dieguez, Rebecca Smith
Early detection and intervention for patients chronic kidney disease could significantly reduce healthcare costs for Medicare and commercial plans.
Article
04 February 2021 - by Susan Silseth, Gabriela Dieguez, Edwin Jonaitis
This white paper studies the impact of formulary restrictions on “walk-away” rates for commercially insured patients prescribed HIV PrEP.
Article
19 November 2020 - by Fernando Mesquida, Gabriela Dieguez, Jorge Torres, Romina Santoro
Es conocido que las comorbilidades se relacionan con una alta proporción de fallecimientos relacionados con el COVID-19 pero hasta ahora no había sido posible cuantificar el efecto de las mismas sobre la mortalidad segmentado por edad y género.
Article
27 October 2020 - by Dane Hansen, Gabriela Dieguez, Nathaniel Jacobson, Emily DeAngelis
This paper examines the role of prescription drug costs in premium increases in the Patient Protection and Affordable Care Act individual and small group marketplaces.
Article
21 October 2020 - by Fernando Mesquida, Gabriela Dieguez, Jorge Torres, Romina Santoro
Milliman used data from Mexico’s Ministry of Health to analyze the increase in the mortality rate produced by COVID-19 by gender, age, and the presence of comorbidities.